FINWIRES · TerminalLIVE
FINWIRES

伍德麦肯兹表示,瓦莱罗炼油厂爆炸后恢复速度加快;关键装置已恢复生产。

By

-- 伍德麦肯兹公司周四表示,瓦莱罗能源公司(VLO)位于亚瑟港、日处理能力为41.5万桶的炼油厂在3月23日发生爆炸导致生产中断一个多月后,正逐步恢复运营。 爆炸损坏了柴油加氢处理装置DHT-243,迫使全厂停产,并启动了分阶段的恢复工作,运营商开始重启部分加工装置。 伍德麦肯兹公司表示,他们利用空中监视和红外监测追踪了恢复进度,数据显示,在工厂各装置陆续重启的同时,重建工作也在进行中。 伍德麦肯兹公司补充说,该炼油厂于4月26日重启了流化催化裂化装置,并于同日开始逐步提高其最大的原油装置的产能,但目前利用率仍低于正常水平。 运营商已逐步提高主要装置的产能,包括一套日处理能力为26.5万桶的原油蒸馏装置和一套日处理能力为17.2万桶的真空蒸馏装置,这些装置的处理能力正在提高,但尚未达到满负荷运转。 多套装置已重启,包括4月2日重启的日处理能力15万桶的常压蒸馏装置(CDU)和4.8万桶的真空蒸馏装置(VDU);4月3日和4月15日分别重启的日处理能力5.7万桶和4.5万桶的加氢裂化装置;以及4月26日重启的日处理能力8万桶的催化裂化装置(FCC)。与此同时,一套日处理能力4.7万桶的柴油加氢处理装置和一套硫磺回收装置仍处于停产状态。 伍德麦肯兹公司补充道,爆炸还影响了邻近的钻石绿可再生柴油厂,该厂依赖于炼油厂的公用设施,不过已于3月下旬恢复运营。 初步损失评估显示,柴油加氢处理装置受损最为严重,该装置结构坍塌,管道大面积变形。 伍德麦肯兹公司表示,附近的装置受损较轻,而爆炸区域内的两座冷却塔和一间控制室则遭受了更为严重的结构性破坏。 维修人员已将工作重心放在冷却塔的重建上,现场可见起重机、脚手架和拆卸作业,承包商正在更换受损部件。 伍德麦肯兹公司表示,尽管取得了进展,但截至4月27日,仍有多个装置处于停产状态,其中包括炼油厂最大的原油蒸馏系统的部分设备,这限制了产能的恢复。 伍德麦肯兹公司补充道,此次长时间的停产加剧了区域燃料市场的紧张局势,因为41.5万桶/日的产能损失恰逢地缘政治紧张局势影响全球供应平衡。 伍德麦肯兹公司表示,其空中和现场联合监测将继续跟踪炼油厂的重启时间表和运营恢复情况。

Related Articles

Research

Research Alert: CFRA Maintains Hold Rating On Shares Of Moderna, Inc. After Q1 Earnings

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:After reviewing Q1 results, we up our target to $48 from $39, based on our NPV analysis. We widen our 2026 LPS view to -$7.95 from -$7.16 and keep our 2027 LPS view at -$4.82. MRNA reported a strong Q1, exceeding revenue expectations and demonstrating significant Y/Y growth. During the analyst call, management highlighted key regulatory approvals in Europe for its respiratory vaccine portfolio and oncology pipeline advancements, which we find encouraging. Despite a GAAP net loss widened by a one-time litigation settlement, underlying financial discipline and cost reduction efforts are noteworthy. Yet, revenue guidance for Q2 is relatively low at $50M-$100M (CFRA: $92M), which points to a 65%-30% Y/Y deceleration (CFRA: 35%) but also signals a significant swing Q/Q after the company recorded $153M in sales in Q1. While we think the progress in the oncology pipeline with the partnership with Merck & Co. (MRK 112 ****) is promising and progressing well, we continue to view MRNA as a wait and see story.

$MRNA
Research

Research Alert: CFRA Maintains Hold Rating On Shares Of Ge Healthcare Technologies Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target to $65 from $87, based on 11.8x our 2027 EPS estimate of $5.51, a sharp discount to the stock's average forward P/E of 18.1x. We cut our 2026 adjusted EPS estimate to $4.86 from $4.96, which stands at the lower end of the reduced guidance range of $4.80-$5.00 (vs. previous $4.95-$5.15). GEHC achieved Q1 organic revenue growth of 2.9% Y/Y, which was at the high end of its expectations. Yet profitability metrics were disappointing with adjusted EPS of $0.99 missing expectations, and the adjusted EBIT margin declining 150 bps Y/Y. This was primarily due to a discrete supplier issue in the PDx business and an unexpected increase in inflationary costs. As a result, GEHC lowered its profit and cash flow outlook, which we view as a prudent move. Strategically, we think GEHC is advancing a strong innovation pipeline, has completed the acquisition of Intelerad, and has announced a reorganization to combine its Imaging and AVS segments into a new segment, which has the potential to accelerate growth.

$GEHC
Research

Research Alert: CFRA Maintains Hold Rating On Shares Of Lennox International Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month target to $569 from $559, 21.4x our 2027 EPS estimate (down to $26.57 from $26.62; our 2026 estimate down to $24.14 from $24.51), near LII's three- and five-year historical forward averages of 21.9x and 20.6x, respectively. We think LII faces material near-term operational challenges from residential market softness, escalating tariff-driven cost inflation (~5% vs. prior ~2.5% guidance), and margin compression in its Home Comfort Solutions segment (390-bp decline to 13.3% in Q1). However, these concerns are substantially mitigated by the Building Climate Solutions segment's exceptional performance (38% revenue growth, 300-bp margin expansion to 19.7% in Q1), significantly improved operating cash flow ($16.1M vs. -$35.8M Y/Y) due to inventory normalization. We note an antitrust class action lawsuit, filed in March, alleging price-fixing among HVAC equipment manufacturers since January 2020, posing an additional risk to LII's financial and reputational standing.

$LII